Hyperuricemia is the biochemical basis for the development of gout and is a serious threat to human life. In this paper， focusing on the relief of hyperuricemia by lactic acid bacteria， the guanosine and inosine degradation ability of 35 strains of lactic acid bacteria was measured， and it was found that four lactic acid bacteria had high degradation ability to guanosine and inosine. Subsequently， the bacterial suspension， contents and metabolites of these four strains were used to the inhibition experiment of xanthine oxidase activity， and the strain with the highest inhibitory ability was selected for whole genome sequencing and safety verification. The experimental results showed that the degradation rates of guanosine and inosine by Lacticaseibacillus rhamnosus JY027 reached 80.27% and 87.33%， and the inhibition rates of the bacterial suspension， contents and metabolites of this strain on xanthine oxidase (XOD) were 85.71%， 78.34% and 84.05%， respectively. This indicated that the strain had strong potential uric acid-lowering ability. In addition， through the whole genome coding gene prediction of Lacticaseibacillus rhamnosus JY027， it was found that the strain has multiple genes related to uric acid metabolism. The safety of the strain was verified by indole， hemolysis and other experiments. This study provides a theoretical basis for the application of Lacticaseibacillus rhamnosus JY027 for relieving hyperuricemia.